Login | Register

Work Area: IP public policy

Countdown to IPBC Korea 2023
Countdown to IPBC Korea 2023

Just one month until IP leaders will gather in  Seoul for an agenda tackling policy developments, market trends, and commercial pressures

We need a better debate about US pharma patents
We need a better debate about US pharma patents

Opinion: Popular attacks on America’s life sciences patent system are highly misleading

Five things to watch in US Supreme Court oral argument in Amgen v Sanofi
Five things to watch in US Supreme Court oral argument in Amgen v Sanofi

Chief IP officers at large and small companies – especially life sciences – are closely watching the case which promises to settle debate about what comprises sufficient enablement under Section 112

Latest content

Legal confusion on essentially derived varieties must be cleared up for the sake of innovation

As gene editing techniques come to the fore in the UK and elsewhere, Joel Smith of Hogan Lovells argues that industry needs clarity on the breeder's exception to plant variety rights

12 May 2022

Japan Patent Office updates SEP licensing negotiation handbook

Comments sought on draft changes to resource, which come just weeks after parent ministry METI issued FRAND guidelines of its own

11 May 2022

Indian patenting milestone should prompt IP policy re-think

Domestic filings outnumbered foreign ones for the first time in 11 years last quarter, in the latest indication that India’s companies are coming to the patent party

07 May 2022

WTO to push for greater covid-19 compulsory licensing flexibilities

Compromise agreed by the US, India, the EU and South Africa leaves trade secrets alone but approves measures that would make it faster and easier to bypass vaccine patents

05 May 2022

IAM insight panel analysis Q1 2022

Featured in Community Insight

After getting a chance to hear from the US president’s pick to lead the USPTO, respondents to IAM’s insight panel swung from negative to neutral

02 May 2022

Pharma, not high-tech, concerns now dominate US patent politics

The first pronouncements from new USPTO Director Kathi Vidal are the latest indication that the centre of gravity in IP debate and policy-making has shifted significantly

30 April 2022

Delaware Judge’s litigation finance disclosure may harm plaintiffs, lead to defence settlements

Patent litigators who represent plaintiffs and defendants agree the new standing order favours the defence, but one litigation financier predicts well-financed patentees backed by reputable lenders will get the upper hand

29 April 2022

How Seagate is working to advance diversity and inclusion in patenting

Nikki Price Shaffer and Bob Pechman share insights on how the computer storage company is using data to understand and address the patent inclusion gap

29 April 2022

Google issues patent policy manifesto as industry gears up for reform debate

Company’s general counsel suggests USPTO fees for the largest filers, like the search giant itself, should be raised

29 April 2022

Vidal suggests tougher scrutiny for pharma patents is in the works

In some of her first public remarks, USPTO director hints at concrete actions the agency could soon take to address perceived patent abuses in life sciences

28 April 2022

Unlock unlimited access to all IAM content

Subscribe Now